Listed Companies > Listed Companies Info. > Main Board Companies > Listed Company Profile
General Stock Board Listed Company Profile
Code:
Industry:
Local/Foreign Company:
6535 LUMOSA
中文
Company Profile
Chairman CEO Spokesperson Tel Address Date of Listing (Regular)
TSAI, CHANG-HAI Lin,Jung Chin JUANG, JUDY SHIN-YI 02-2655-7918 4F, NO. 3-2, PARK ST., NANGANG DIST.,TAIPEI CITY, TAIWAN 2016/09/26
Industry Main Business
Biotechnology and Medical Care
Lumosa Therapeutics is dedicated to the development of innovative new drugs for the treatment of unmet medical needs in the fields of CNS and inflammatory diseases. The company is also actively engaged in scientific licensing and collaboration of first-in-class drug development. Lumosa has an experienced and well-integrated R&D and Business Development team; consist of professionals in chemical development, CMC, preclinical development, translational research, clinical development, regulatory affairs and project management, as well as intellectual property and business development.
 
Market Information ( 2020/08/10 )
Shr. Vol. Highest Lowest Closed Change Transaction TurnOver(%) long
margin
balance
(1,000shr.)
Short
margin
balance
(1,000shr.)
949.907 42.20  39.95  40.30  -1.90  584 0.80 N/A N/A
Trading method Fun
purchase
price or
securities
pneeded
on T day
Announcement of Irregularity
(2020/08/10)
TPEx measures
adopted
(2020/08/10)
With warrants Can be shorted or margined? Detail
Normal N N N N N Today History
 
Financial Reports
Cash Flows Items
Amount
(NT$ thousand)
Cash flows from operating activities
Cash flows from investing activities
Cash flows from financing activities
Balance
Sheets
Current assets
Non-current assets
Total assets
Current liabilities
Non-current liabilities
Total liabilities
Share capital
Capital surplus
Retained earnings
Other equity interest
Treasury shares
Total equity attributable to owners of parent
Non-controlling interests
Total equity
Book Value per share(NT$)
Comprehensive Income Operating revenue
Operating costs
Gross profit from operations
Operating expenses
Net other income (expenses)
Net operating income
Non-operating income and expenses
Profit before tax
Tax expense
Profit from continuing operations
Profit from discontinued operations
Profit
Other comprehensive income
Comprehensive income
Basic earnings per share
* Auditor's report on latest financial statements: auditor's report:
* More detail:MOPS
* Foreign issuers’ information is disclosed in consolidated statements.